Video Lectures

The video lectures below are provided as an educational opportunity and resource for laboratory professionals. “Current video lectures” provide FREE continuing education credits upon the completion of a quiz which is provided after the video is viewed in its entirety. The quiz must be passed with a score of 80 percent or higher to obtain credit.


Credit Types Available: (click icon to filter)
C = CME |  S = SAM |  P = P.A.C.E.® |  F = Florida | Show All |


 
Video Lecture Credit Types
Lab Stewardship JeoPARODY
Number of Credits: 1.0

Laboratory stewardship, which has evolved from its predecessor of utilization management, is rapidly becoming an essential tool in the clinical laboratory’s arsenal for improving quality patient care. This presentation looks at broad laboratory stewardship topics using the format first popularized by the game show Jeopardy!™. Using this format provides a fun, engaging, and entertaining experience for learners. Our “show” is hosted by Dr. Mike Astion, a widely known and published expert on laboratory stewardship, co-founder of PLUGS (Patient-centered Laboratory Utilization Guidance Services), and Medical Director of Seattle Children’s Hospital Department of Laboratories. Timely and relevant commentary is provided by Dr. Jane Dickerson who is a co-founder of PLUGS and Director of Clinical Services at Seattle Children’s Hospital and Dr. Andrew Fletcher who is the Medical Director of Consultative Services at ARUP Laboratories and also widely known and published expert in laboratory stewardship.

C S P F
Interesting Cases from the U of U Rad-Path Conference 2019: Differentiating Challenging Entities by Rachel E. Factor, MD, MHS and Eugene Kim, MD
Number of Credits: 1.0

A radiology/pathology conference is a way for two disciplines to share their thinking process and learn from each other in how a differential is reached. In the this talk, we chose 3 recently received cases, that happen to be rare but described entities in the breast. Each has important differential diagnoses to exclude. We describe radiologic and histologic features, the differential, and relevant ancillary tests, such as immunohistochemistry and molecular tests, which help arrive at the ultimate diagnosis for each case.

C S P F
GI Lymphomas: EATL, MALT and Beyond by Maria A. Pletneva, MD, PhD
Number of Credits: 1.0

Gastrointestinal lymphomas often present a diagnostic difficulty for the surgical pathologist for variety of reasons. In this presentation, we will discuss the aspects of such difficulties, review specific examples of lymphomas involving the GI tract, review relevant topics from the WHO2016 update to the Classification of Tumors of Haematopoietic and Lymphoid Tissues, and propose a rational and pragmatic approach to making a diagnosis.

C S P F
Laboratory Evolution and Adaptation to Telemedicine: Are We Blockbuster in a Netflix World? by Andrew Fletcher, MD, MBA, CPE, CHCQM, FCAP
Number of Credits: 0.5

This webinar will review the results from existing telemedicine adoption surveys, the impact to laboratory volumes and review the results of the recently executed ARUP Telemedicine survey. Additionally a case study will be presented to provide a comparison from another industry exploring the impact of diffusion of innovation on market share.

C S P F
Introduction to Cytogenetics: Part 1 by Erica Andersen, PhD, FACMG
Number of Credits: 1.0

This two-part series provides an introduction to the science of cytogenetics. Cytogenetics is the study of chromosomes, genomic structure, function and variation, and the role of these aspects in human disease and heredity. Explanations will include the basics of technologies of chromosome analysis and karyotyping.

C S P F
Introduction to Cytogenetics: Part 2 by Erica Andersen, PhD, FACMG
Number of Credits: 1.5

This two-part series provides an introduction to the science of cytogenetics. Cytogenetics is the study of chromosomes, genomic structure, function and variation, and the role of these aspects in human disease and heredity. Explanations will include the basics of technologies of chromosome analysis and karyotyping.

C S P F
The State of the Dysplastic Nevus in the 21st Century by Keith Duffy, MD
Number of Credits: CME/SAM: 1.25 PACE: 1.0 Florida: 1.2

The dysplastic nevus has been the source of much controversy and debate since the term was coined in the 1970’s. Many studies regarding this histologic entity have been performed over the years and the debate still exists about proper diagnosis and management of these nevi. The lecture will elucidate some of the recent advances in understanding these distinct entities and their relationship to melanoma risk.

C S P F
Focused Updates in the Surgical Management of Breast Cancer by Jane M. Porretta, MD, FACS
Number of Credits: CME/SAM: 0.75 PACE: 0.5

Breast surgery has evolved significantly in the past several years with new treatments focusing on efficiency and accuracy in surgery, reducing morbidity and improving cosmetic outcomes for breast cancer patients.

New techniques for localizing nonpalpable breast cancer lesions have been developed that ease the work flow and scheduling of lumpectomy procedures.

Based upon large scale metanalysis there is a consensus on adequate margins for breast cancer lumpectomy margins. There are various methods that surgeons can employ to achieve negative surgical margins and reduce re excision rates.

Sentinel node biopsy has revolutionized axillary staging in early breast cancer and newer studies are showing that axillary dissection may have little benefit for most patients. Current studies are looking at utility of axillary dissection in patients who present with clinically positive axillary nodes and receive neoadjuvant chemotherapy.

Good cosmetic results in breast cancer surgery are important to patient well- being and satisfaction. New techniques to improve these results have been a welcome change in breast cancer surgery and oncoplastic and nipple sparing techniques are shown to be safe oncologic procedures as well.

C S P F
Selling Lab Services: Experiences and Nuggets of Wisdom by Peter T. Francis
Number of Credits: 1.0

Marketing in the reference laboratory industry has evolved over the past 50 years. In the early days, sales reps and upper management had to develop new and effective strategies and tactics that centered on selling a healthcare service as opposed to a product, such as equipment or pharmaceuticals. As such, lab sales reps have learned significant lessons over the years from those nascent times. The listener—either experienced or not—should find some nuggets of wisdom in this presentation that will help him/her grow their business as well as prevent the loss of an account to a competitor.

C S P F
Genetic Data Sharing and Reanalysis of Genomic Test Results: Challenges and Benefits to Implementation by Erica Andersen, PhD, FACMG and Rong Mao, MD, FACMG
Number of Credits: 1.0

Clinical laboratories are increasingly called upon to share genetic testing data, as well as reevaluate results from previously performed tests for hereditary conditions. These efforts create unique opportunities and challenges during the diagnostic workup for new and previously tested patients. This presentation will provide an overview of current practices and policies surrounding genetic data sharing and variant reanalysis, with shared stories on successes and hurdles overcome to help patients with rare genetic disorders end their diagnostic odyssey.

C S P F
Microscopy of CSF and Body Fluids by Tracy I. George, MD
Number of Credits: 1.0

In this lecture Dr. Tracy George focuses on the microscopy of cerebrospinal fluid, pleural fluid, peritoneal fluid, and pericardial fluid. Both normal and abnormal cell types will be shown and features that help distinguish benign from malignant cytology will be discussed. Recommendations for additional ancillary studies will also be explored.

C S P F
NIFTP and the Updated Bethesda System for Thyroid FNA by Jeffrey F. Krane, MD, PhD
Number of Credits: 1.0

This presentation will discuss the development and underlying rationale for developing the terminology of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Criteria for recognizing NIFTP in surgical pathology will be discussed as will the implications for NIFTP for thyroid FNA. Updates to the second edition of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) will be discussed including the impact of the NIFTP terminology.

C S P F
CLIA Regulations by Lauren Pearson, DO, MPH
Number of Credits: 0.5

This presentation will provide an overview of the Clinical Laboratory Improvement Amendments (CLIA) regulations described in Title 42, Part 493 of the Code of Federal Regulations along with basic CLIA standards and requirements for laboratory certification and/or accreditation.

C S P F
The Role of the Clinical Laboratory in the Current Opioid Epidemic by Skyler J. Simpson, MD
Number of Credits: 1.0

Opioid medication abuse and misuse is a major cause of morbidity and mortality in the United States. The clinical laboratory plays a vital role as the healthcare system in the United States deals with the current opioid epidemic. This lecture is intended to help medical laboratory scientists gain a basic understanding of clinical uses of opioid medications, the short- and long-term effects of opioid use, and the different scenarios for performance of opioid testing for patients. In addition, this lecture covers laboratory testing methods for opioids and includes clinical cases to illustrate how test results can be combined with clinical information to determine individual drug use patterns in order to help build physician-patient relationships.

C S P F
Molecular Diagnostics in Cytology and Small Biopsy Specimens of Non-Small Cell Lung Cancer by Georgios Deftereos, MD
Number of Credits: 1.0

Non-small cell lung cancer is among the most common cancer types in males and females, in the US and worldwide, and currently has the highest mortality among all cancer types. Guidelines are continuously updated to reflect the most current state of knowledge on biomarker testing in this setting, and updated recommendations are in place as to what testing needs to be performed, based on pathological diagnosis and clinical presentation, along with what specimens can be tested and what characteristics the testing platforms utilized need to have. As the number of possibly actionable tests to be performed is increasing, it is important for the clinician and the pathologist to have an understanding of the clinical and technical aspect of this testing, in order to optimize the way specimens are procured and utilized for testing, especially in the setting of cytology and small biopsy specimens that are very common in lung cancer.

C S P F
Practical Molecular Pathology: Colon Cancer by Wade Samowitz, MD
Number of Credits: 1.0

The molecular diagnostics of colorectal cancer has important clinical implications for the detection of Lynch syndrome and for treatment of colorectal cancer. Detection of mismatch repair deficiency, either by PCR or immunohistochemistry, is the current first step in the Lynch syndrome tissue work-up. Subsequent evaluation of BRAF mutation status and MLH1 methylation help assess whether a mismatch repair deficient tumor is sporadic or potentially Lynch-associated. Mismatch repair deficiency is also associated with a good prognosis and a response to immunotherapy. Finally, evaluation of the EGFR pathway, in particular mutations in KRAS and NRAS, is useful to determine the potential efficacy of therapy with EGFR inhibitors.

C S P F
Urine Toxicology Testing to Support Pain Management and Treatment for Substance Use Disorder by Yifei Yang, PhD, DABCC
Number of Credits: 1.0

As controlled substances are prescribed in pain management and addiction treatment settings, urine drug testing is frequently adopted to monitor and assure clinical adherence to treatment plans. The purpose of such testing is to verify expected drug use, in addition to identify unexpected drug use. Because the clinical utility is different from traditional drug of abuse testing, the testing strategy and approaches are designed accordingly to minimize both “false positive” and “false negative” results. Based on the clinical utility of different drugs detected, the analytical workflow can be further adopted to optimize sensitivity and specificity of each individual drug.

C S P F
Unusual and Challenging Cases in Genitourinary Pathology by Daniel Albertson, MD
Number of Credits: 0.5

This lecture will discuss uncommon variants of select genitourinary tumors of testis/paratesticular and renal/perirenal tissues with a focus on the differential diagnosis, key morphologic features, and when appropriate, ancillary testing.

C S P F
Moving Forward from the COVID-19 Crisis: Laboratory Trends and Challenges by Sandy Richman, MBA, C(ASCP) and David Shiembob, MBA, C(ASCP)CM
Number of Credits: CME/SAM: 1.25 PACE: 1.0 Florida: 1.3

The world has changed dramatically since the start of the COVID-19 pandemic, and this may be especially true of the clinical laboratory industry. Laboratories across the country have been caught in an extraordinary and contradictory set of circumstances—overwhelming pressure and demand for COVID-19 testing that has often been impossible to fulfill, coupled with crashing revenue and test volumes as patients across the country have been told to “shelter in place.” Join us for this webinar as the ARUP Consultative Services team speaks with a panel of laboratory leaders throughout the country to explore what’s changed in the industry, how laboratories can adapt, and what the future holds.

C S P F
Spindle Cell Conundrums in the Chest by Henry D. Tazelaar, MD
Number of Credits: 1.0

Spindle cell proliferations in the lung and pleura range from benign easily treatable diseases to malignancies with very short survivals. The samples are also very limited in many instances, making immunohistochemical triage a priority. The lecture will discuss the most common spindle cell processes encountered in lung and pleural samples and offer a reasonable way to work up individual cases without using up valuable tissue.

C S P F
PGx and TDM in Psychopharmacology by Gwendolyn A. McMillin, PhD, DABCC(CC,TC)
Number of Credits: 1.0

The optimization of pharmacy decisions is often based on trial-and-error, which may require several weeks to months for many drugs used in psychiatry due to less than desirable response, side effects, and potentially life-threatening toxicity. There are many medications available to treat depression, anxiety, schizophrenia, attention deficit and other behavioral health conditions. Research has shown that pharmacogenomics (PGx) and therapeutic drug monitoring (TDM) can help to inform drug and dose selections. This presentation will provide a background on PGx and TDM laboratory tests, along with some examples of how these tools are relevant to behavioral health.

C S P F
Carbapenem Resistance and Carbapenemase Detection in the Clinical Microbiology Lab by Rebekah M. Martin, PhD, MLS(ASCP)CM
Number of Credits: 1.5

Antimicrobial resistance has been recognized by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) as a major global public health problem. Carbapenem resistance, a type of antimicrobial resistance, has been designated an urgent threat to public health here in the United States. Of particular concern are organisms that harbor transmissible genes encoding carbapenemase enzymes. Determining if an organism produces a carbapenemase and identifying which carbapenemase is produced can help guide antibiotic therapy in patients infected with these organisms, and can also be useful epidemiologically.

This talk will discuss carbapenem resistance mediated by carbapenemase production, and will provide information on several current test methods for the detection of carbapenemases in the clinical microbiology laboratory. Activity of newer antibiotics against individual classes of carbapenemases will also be discussed.

C S P F
Molecular Tools in the Diagnosis of Lymphoma by Kristin Karner, MD
Number of Credits: 1.0

Learners will become familiar with current algorithms including immunohistochemistry and FISH testing in the work-up of diffuse large B-cell lymphoma, one of the most common lymphomas a pathologist is likely to encounter in routine practice. We will also discuss B-cell and T-cell clonality testing including how the assays work, when to use them and what the pitfalls are in ordering and interpreting these assays. Learners will leave with a better understanding of how these ancillary tests can be used in the work-up of lymphomas.

C S P F
Small Bowel Malabsorptive Disorders: Celiac Disease and Other Entities by John Hart, MD
Number of Credits: 1.0

Celiac disease is a common and underdiagnosed small bowel disorder with a myriad of presenting signs and symptoms. There are also many clinically significant diseases that can resemble celiac disease histologically. Recent advances in the diagnosis of celiac disease and other small bowel malabsorptive disorders will be discussed, and the utility of key laboratory and clinical features will also be presented.

C S P F
Practical Molecular Pathology: GI tract by Georgios Deftereos, MD, FCAP, FASCP
Number of Credits: 1.0

This lecture will focus on three areas of practical molecular pathology for the gastrointestinal (GI) tract:

  1. PD-L1 testing in the gastrointestinal tract, with practical information on ordering criteria, interpretation and specimen submission for testing. This will focus on the recent FDA approval of PD-L1 testing for immunotherapy in gastroesophageal adenocarcinomas, as well as other indications for testing and treatment in other GI malignancies.
  2. Molecular pathology of gastrointestinal stromal tumors (GISTs), with emphasis on the spectrum of genetic alterations seen in GISTs, and their management implications.
  3. Her2 testing in gastroesophageal adenocarcinomas, with emphasis on the current CAP-ASCP-ASCO guidelines.

C S P F
Laboratory Stewardship and Order Set Optimization by Andrew Fletcher, MD, MBA, CPE and Jennifer Tincher, MBA
Number of Credits: 1.0

During this presentation, we will discuss how order sets impact the laboratory and examine specific issues regarding test ordering. Next, we will explore an example of an efficient order set development/maintenance process and highlight how the laboratory can contribute. Physician preference items (“favorites”) will also be discussed as well as possible solutions for optimization. We will offer specific examples of laboratory order set initiatives and optimization so that laboratorians can begin driving quality and cost reduction in their healthcare systems.

C S P F
Extreme Molecular Diagnostics by Carl T. Wittwer, MD, PhD
Number of Credits: 1.0

Extreme molecular diagnostics takes only seconds. With very short turn-around times, pre-analytical and post-analytical challenges are minimized, point-of-care testing makes sense, and high-throughput is not necessary. Extreme PCR in <15 seconds, high speed melting analysis in 4 seconds, and rapid sample preparation enable sample-to-answer diagnostics in <1 minute.

C S P F
Hippocratic Capitalism: An Ethical Marriage of Health and Tech by Brian R. Jackson, MD, MS
Number of Credits: 0.5

This presentation describes a pathway for health care technology companies to incorporate medical ethics into their business strategy. It provides counterexamples of health technology companies who failed to prioritize patient interests, and ultimately failed financially as a result. The medical ethical principles of respect for persons, beneficence and justice are briefly described, along with illustrations from the information technology sector.

C S P F
Work Up of Acute Leukemia by Archana Agarwal, MD
Number of Credits: 1.0

Laboratory evaluation of acute leukemia although critical, is complex and is constantly evolving due to advancement in understanding the molecular basis of leukemia. Its implication is not only for diagnosis, but also for therapeutic and prognostic purposes. In recognition of the complexity of these testing algorithm, College of American Pathologists and American Society of Hematology have come up with guidelines to help clinician and pathologist in initial evaluation of acute leukemia. This presentation focuses on the classification, sample requirements and the tests needed on every patients as well as on a subset of patients. Prognostic and therapeutic implications of these newer molecular tests would be discussed briefly.

C S P F
Best Practice Immunohistochemistry in Diagnosis of Urological Tumors by Mahul Amin, MD
Number of Credits: 1.0

This lecture will help the practicing pathologist develop a best practice standard with regards to immunohistochemical stain usage in the urologic tract, specifically bladder, prostate and kidney. Immunohistochemistry should help guide and add to, but not dictate, a diagnosis. Thus, accurately integrating an immunopanel’s results into the clinical history, gross examination and microscopy requires understanding when to order and how to appropriately interpret immunohistochemical stains. Differentiating between benign tissue, reactive processes and various urinary tract malignancies is the focus of this lecture.

C S P F
Rapid Antimicrobial Susceptibility Testing by Mark Fisher, PhD, D(ABMM)
Number of Credits: 1.0

Antimicrobial susceptibility testing (AST) results have a significant impact when managing patients with serious infections. Recent developments in identification tools can now identify microbes with unprecedented speed, but phenotypic susceptibility testing has lagged behind. New phenotypic AST systems are being introduced with the promise of improving current molecular tests by rapidly measuring inhibition of growth across panels of antibiotics. In this presentation, we will explore the technology, performance, and impact on patient care of these new, rapid AST methods.

C S P F
Ethical Challenges from Medical Big Data and AI by Brian R. Jackson, MD, MS
Number of Credits: 0.5

Big data and artificial intelligence are revolutionizing most areas of society, and are poised to make a similar impact on health care and medicine. Like all new powerful technologies, AI has risks as well as benefits. If not carefully managed, AI can contribute to serious harm to patients in areas including privacy and nosocomial injury. This presentation will describe the nature of these risks along with potential approaches to reduce harm.

C S P F
Innate Immune Responses Contribute to Host Defense, Disease, and Repair in Response to Viral Infection of the CNS by Thomas E. Lane, PhD
Number of Credits: 1.0

Viral infection of the central nervous system (CNS) results in a number of different clinical outcomes ranging from benign infection to life-threatening conditions as well as insidious disease characterized by viral persistence with potential for life-long neurological complications. Importantly, the past 20 years has recognized the emergence of neurotropic viruses that have caused a myriad of clinical problems and raised public awareness of the importance of studying viruses that infect the CNS. We employ infection of susceptible mice with the neurotropic JHM strain of mouse hepatitis virus (JHMV) to better understand the molecular and cellular mechanisms influencing host defense, demyelination, and remyelination. While the adaptive immune response is critical in effectively controlling viral replication as well as contributing to neurodegeneration, the contributions of the innate immune response to these processes is less well understood. We have recently determined that both neutrophils and microglia are important contributors in optimizing host defense following JHMV infection. In addition, we’ve shown that sustained infiltration of neutrophils into the CNS augments demyelination whereas microglia ablation limits the severity of white matter damage and restricts remyelination. We are currently attempting to address the mechanisms by which neutrophils and microglia influence these two separate events.

C S P F
Molecular Subtypes of Renal Cell Carcinomas by Deepika Sirohi, MD
Number of Credits: CME/SAM: 0.75 PACE: 0.5

Large scale sequencing studies have expanded our understanding of renal cell carcinomas; identifying new information of the genomic landscape across different renal cell carcinoma subtypes. As research in this field unfolds, discoveries from these studies have had significant impact in not only identifying diagnostic molecular alteration, but also prognostic subcategories and therapeutically targetable genomic alterations. This talk will review the emerging genomic landscape of renal cell carcinomas, provide an overview of an integrative approach to molecular subtyping of this subset of tumors and the challenges and limitations of this approach, and address the role of a multi-omics approach in precision medicine for renal cancers.

C S P F
Who’s WHO in the new WHO Classification of Urologic Cancer? by Mahul Amin, MD
Number of Credits: 1.0

This lecture will focus on the updates and new classifications relating to the WHO 2016 (4th edition) in Genitourinary tumors. The revised classifications have been implemented to better predict prognosis and treatment strategies for patients with various genitourinary tumors. The lecture will also introduce novel molecular profiling of tumors that relate to specific histologic tumor types.

C S P F
What’s New in Inflammatory and Fibrotic Lung Disease? by Henry D. Tazelaar, MD
Number of Credits: 1.0

Organizing pneumonia is not a new diagnosis but histologic variation can make recognition challenging. The hyalinized variant and its differential will be emphasized. In addition, granulomatous lung disease includes a few new entities, less familiar to general pathologists, but even rudimentary knowledge of them can help narrow the differential diagnosis in certain circumstances e.g. lung disease in common variable immunodeficiency, and primary biliary cholangitis. Finally, the lecture will focus on lung toxicity in patients on immune check point inhibitors.

C S P F
Doctor of Clinical Laboratory Science (DCLS): Contributing Quality and Value in Clinical Laboratory Services Delivery by Nadine A. Fydryszewski, PhD, MS, MLS(ASCP)CM and Brandy Gunsolus, DCLS, MLS(ASCP)CM
Number of Credits: 1.0

The Doctor of Clinical Laboratory Science (DCLS) is an advanced practice healthcare practitioner dedicated to increasing the value of diagnostics through consultation as members of interprofessional healthcare teams and conducting research focused on evidence of the impact of diagnostics on healthcare outcomes. As a member of interprofessional healthcare teams, the DCLS contributes by providing consultation to assure quality & value improvement in utilization and delivery of laboratory services. Consultation occurs in a variety of setting as described in the Diagnostics Consultation Model©. Case examples will demonstrate the value of the DCLS consult to quality patient care, safety, laboratory utilization and cost outcomes.

C S P F
Selected Cases in Inflammatory Dermatopathology by Scott Florell, MD
Number of Credits: 1.0

There are hundreds of inflammatory skin diseases making inflammatory dermatopathology quite challenging. Appropriate diagnosis of cutaneous eruptions requires appropriate sampling of the eruption and careful clinical-pathologic correlation.

C S P F
What Has Changed (again) in HER2 Testing of Breast Cancers by Evin Gulbahce, MD
Number of Credits: 1.0

Since HER2 directed therapies became available for treatment of breast cancer, determining HER2 status of breast cancers has been an area of challenge and controversy. Changes in guidelines of HER2 testing and interpretation have contributed to the uncertainty in defining what is HER2 positive. This lecture will review briefly the history of HER2 testing and the most recent clinical evidence leading to the 2018 ASCO/CAP update of HER2 testing in breast cancer.

C S P F
Moving Beyond Single Gene-Drug Pairs in Clinical Pharmacogenomics Testing by Yuan Ji, PhD, DABCP, FACMG and Gwendolyn A. McMillin, PhD
Number of Credits: 1.0

Pharmacogenomics (PGx) studies the associations between discrete variants in single genes and the phenotype for specific aspects of a drug’s pharmacokinetics or pharmacodynamics. These associations are used to qualify patients for therapy (e.g., CYP2C19 and clopidogrel), to avoid drug-related adverse events (e.g., TPMT and mercaptopurines), and to optimize drug and dose selection (e.g., CYP2D6 and several antidepressants). However, clinical PGx testing based on single gene-drug associations has limited clinical utility when patients take more than one medication. For some drugs, limitations of single gene-drug associations may be mitigated by combining the testing of several pharmacogenes based on single gene-drug associations along with clinical and demographic factors. Emerging evidence shows the benefits of multi-gene panels in clinical PGx testing. This presentation will review examples of single and multi-gene PGx testing applied to drug therapy decisions.

C S P F
Lab & Pharmacy: Turning Daily Interaction into a Partnership by Danielle C. Kauffman, PharmD, MBA
Number of Credits: CME/SAM: 0.75 PACE: 0.5

Lab and pharmacy interact on a daily basis, whether intentionally or incidentally. Identifying these areas is a starting point for a more collaborative partnership in patient care activities. There are also many benefits to each department and the hospital overall. In addition, emerging, high profile initiatives depend heavily upon teamwork and leadership from both lab and pharmacy for success.

C S P F
Emerging NGS Applications at the Intersection Germline and Somatic Cancer Genetics by Colin C. Pritchard MD, PhD
Number of Credits: CME/SAM: 1.25 PACE: 1.0 Florida: 1.2

Next generation sequencing (NGS) has enabled increasing use of cancer genetic testing for both germline cancer predisposition and somatic mutation profiling in tumors. This presentation will cover emerging clinical applications of NGS in oncology at the intersection between germline and somatic findings. These emerging areas include paired tumor and germline testing of BRCA1, BRCA2, and mismatch repair genes to guide cancer treatment decisions, microsatellite instability testing by NGS, and tumor sequencing to assist in a germline cancer predisposition workup.

C S P F
Harnessing the Host Response for Real Time Clinical Decision Making in Infectious Diseases by Christopher W. Woods, MD, MPH, FIDSA
Number of Credits: 1.0

In his lecture, Dr. Woods will describe the emerging pandemic of antimicrobial resistance and how his 20-year obsession with developing improved diagnostics for infectious diseases addresses the problem. In particular, he will discuss the derivation of host mRNA signatures, their translation to new diagnostic platforms, and the clinical trials designed to assess their performance.

C S P F
Metagenomics for Universal Pathogen Detection by Robert Schlaberg, MD, Dr Med, MPH
Number of Credits: 0.5

Metagenomics, the genomic analysis of a population of microorganisms, makes possible the profiling of microbial communities in the environment and the human body at unprecedented depth and breadth. Its rapidly expanding use is revolutionizing our understanding of microbial diversity in natural and man-made environments and is linking microbial community profiles with health and disease. In addition, recent progress in rapid and accurate data analysis has also demonstrated promise of metagenomics-based approaches for universal pathogen detection in routine patient samples. This lecture discusses approaches, promises, and challenges for the use of metagenomics-based tests in diagnostic laboratories.

C S P F
Resolution of ABO Discrepancies by Justin R. Rhees, MS, MLS(ASCP)CM, SBBCM
Number of Credits: 1.0

It is crucial to correctly identify ABO discrepancies. All ABO discrepancies must be investigated and the underlying cause identified before a patient or donor’s correct blood type can be resulted.

C S P F
Gynecologic and Gastrointestinal Pathology: Pitfalls and Pearls in Frozen Section Diagnosis by Joanna Savage, MD
Number of Credits: 1.0

Practicing pathologists will improve their knowledge regarding the strengths and limitations of the gynecologic frozen section. Basic clinical decision making points are also discussed throughout the lecture in order to help the pathologist better guide the surgeon during the intraoperative consultation.

C S P F
CRISPR and Diagnostics: Challenges and Strategies for Understanding Results from Sequencing including Variants of Unknown Significance by Joshua L. Bonkowsky, MD, PhD
Number of Credits: 1.0

Diagnosis of disease has been revolutionized by next-generation sequencing (NGS) tools, but their use presents challenges to the clinician and to the laboratory. We discuss rationale approaches to diagnosis based on data; the use of exome, whole genome, and gene panel testing; and the hurdles created by identification of novel genes, mutations, and variants of unknown significance (VUS). Finally, we present and discuss the use of CRISPR, other novel technologies, and available resources, that can address the avalanche of data from NGS.

C S P F
Help! What do I do with those Granulomas in the Lung? by Henry D. Tazelaar, MD
Number of Credits: 1.0

Granulomatous lung disease is a common problem in surgical pathology and the differential is broad. When stains and cultures are negative, one needs an approach to guide clinical decision making. The lecture will highlight a practical, proven approach to interpreting large and small granulomas in a way that will be most helpful to your clinicians and patients.

C S P F
Big Data: Genomic Reference Databases to Empower Mendelian Diagnosis by Anne O’Donnell-Luria, MD, PhD
Number of Credits: 1.0

This presentation will discuss how large scale reference population databases have improved molecular diagnoses and variant interpretation. By evaluating where variation is missing from the general population, candidate disease genes constrained for loss of function and missense variation have been identified. We have developed a frequency filtering approach to determine when a variant is to common in the general population to cause a given disease.

C S P F
Appendiceal GCC and LAMN: Navigating the Alphabet Soup in the Appendix by Sanjay Kakar, MD
Number of Credits: CME/SAM: 0.75 PACE: 0.5

Discuss the terminology, morphologic criteria, staging schemes and common pitfalls in the diagnosis and treatment of appendiceal mucinous tumors and goblet cell tumors.

C S P F
Staging Updates in AJCC 8th ed Colorectal and Selected GI Sites by Sanjay Kakar, MD
Number of Credits: 1.0

Commonly encountered problems in the staging of colorectal and hepatobiliary cancers will be discussed with a focus on rationale for changes in the AJCC 8th edition and new parameters in the CAP synoptics.

C S P F
Case Studies in Lab Acquisitions—The Impact on Clinical and Lab Operations by Brian R. Jackson, MD, MS; Ladonna Bradley, MT(ASCP); and Steven Serota
Number of Credits: 1.0

This panel discussion will cover some different outsourcing arrangements offered by commercial laboratories, focusing specifically on the impacts to laboratory personnel, clinician satisfaction, and patient care.

This video lecture is part three of a three-part series entitled "Don't Sell Your Lab Short."




C S P F
A Business Perspective of Laboratory Outsourcing Arrangements by Golden Welch, BS, MT(ASCP) and Sandy Richman, MBA, C(ASCP)
Number of Credits: 1.0

Outsourcing laboratory services can produce short-term cost savings with long-term consequences. This presentation will describe economic and other factors that drive outsourcing arrangements, as well as economic and operational risks. Presenters will also discuss ways to articulate the value of the laboratory to administrators and executives.

This video lecture is part two of a three-part series entitled "Don't Sell Your Lab Short."




C S P F
How to Make Smart Insourcing and Outsourcing Decisions for Hospital Laboratory Services by Brian R. Jackson, MD, MS
Number of Credits: 1.0

Does your lab currently obtain tests or other services from an outside vendor that could potentially be insourced? Or has your lab or hospital considered outsourcing some or all lab services to an outside company? These types of decisions are extremely common throughout healthcare, and they’re often driven by top-down financial analyses, which, in some cases, leads to disastrous outcomes. This presentation will provide examples from healthcare and other industries to show how a more holistic approach to cost analysis can lead to better insourcing and outsourcing decisions.

This video lecture is part one of a three-part series entitled "Don't Sell Your Lab Short."




C S P F
Ordering the Right Lab Test: It all begins with the Right Test Name by Ila Singh, MD, PhD
Number of Credits: 1.0

Names for lab tests have traditionally been chosen by clinical pathologists and scientists. While these test names make perfect sense to anyone in the clinical laboratories, that is not always the case with clinicians. Clinicians often order the wrong test or a sub-optimal test, or more tests than necessary, because the relevant test names are unclear or obscure. Often the wrong orders lead to safety and quality issues. Many hospital Utilization Management (UM) or Lab Stewardship efforts focus on correcting such test names, which is typically a slow and non-trivial process, as no standardized lab names exist.

This talk will discuss solutions to non-standard lab names, namely, TRUU-Lab, a collaborative effort among pathologists, clinicians, professional organizations, accreditation agencies, large reference labs and terminology groups to create a consensus guideline for giving laboratory test more rational and consistent names. The ultimate goal is to bring this consistency and ease of use into electronic health records (EHR) and laboratory information systems (LIS).

C S P F
Fatty Liver Disease: Diagnostic Challenges and Updates by Ryan M. Gill, MD, PhD
Number of Credits: 1.0

Non-alcoholic fatty liver disease (NAFLD) indicates evidence of fat in the liver, either by imaging or histology, in a patient without a reason to have secondary fat accumulation (e.g. significant alcohol consumption, use of certain medications, or inherited storage defects, etc). Histologic examination of liver tissue is required to sub-classify NAFLD as non-alcoholic fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH). NAFL represents steatosis without histologic liver injury while NASH represents steatosis with histologic evidence of liver injury (i.e. ballooned hepatocytes, inflammation, and fibrosis).

Non-alcoholic steatohepatitis (NASH) key pathologic features:

  • Steatosis >5%
  • Inflammation (lobular)
  • Hepatocellular injury (ballooned hepatocytes)

The risk of progression to advanced fibrosis in NAFL is minimal while in NASH, progression to cirrhosis and/or development of hepatocellular carcinoma (HCC) is well described. NASH cirrhosis is defined as cirrhosis with current or previous evidence of NAFLD. Risk factors for NASH include metabolic syndrome, dyslipidemia, diabetes mellitus type 2, and obesity. There are no clinical or radiological tests that can reliably diagnose steatohepatitis and serum transaminases often correlate poorly with biopsy findings. Histologic diagnosis remains the gold standard for diagnosis of NASH. It is important to recognize diagnostic pitfalls in evaluating NAFLD biopsies and to appreciate the role of scoring systems used in clinical trials.

C S P F
Dysplasia of the Gastrointestinal Tract: Pitfalls and Solutions by Mary Bronner, MD
Number of Credits: CME/SAM: 1.25 PACE: 1.0 Florida: 1.3

This presentation will cover dysplasia arising in chronic inflammatory disorders of the gastrointestinal tract, including Barrett’s esophagus, idiopathic inflammatory bowel disease IIIBD), pangastric intestinalized Helicobacter pylori gastritis. Covered topics will include the intestinal and gastric types of Barrett’s dysplasia, dysplasia grading, pitfalls for over diagnosing and over grading dysplasia, broadening therapies for Barrett’s neoplasia and the impact of this on pathology practice, the split muscularis mucosae in Barrett’s, the problems with dysplasia diagnosis, in differences between Barrett’s and IBD neoplasia, visible lesions in IIBD dysplasia, natural history data on dysplasia, improved biomarkers of cancer risk, adequate surveillance biopsies, and treatment options. If time permits, the diagnosis and management of colorectal adenocarcinoma in polypectomy specimens will be reviewed.

C S P F
Rapid Sequencing of Known Mendelian Genes in NICU by Rong Mao, MD, FACMG
Number of Credits: 1.0

A significant fraction of the 4,000 known single-gene disorders manifest symptoms in newborns. A rapid diagnosis of newborn diseases could make the difference between life and death, as well as reduce length of stay in the neonatal intensive care unit (NICU). A targeted panel of ~4,900 known disease-causing genes has been developed with a short turnaround time and a focused interpretation. This panel combines genetics etiology with phenotype to provide a comprehensive clinical understanding of disease in NICU.

C S P F
Adventures in Laboratory Stewardship: Improving Quality and Care while Lowering Costs by Gary W. Procop, MD, MS
Number of Credits: 1.0

This session will discuss many of the interventions undertaken by the speaker at his institution to improve care delivery through laboratory stewardship interventions. Emphasis will be placed on laboratory leadership, collaboration with clinical colleagues, the importance of communication and professionalism, and a systems-based approach to problem solving. Evidence will be presented that these interventions, in addition to promoting healthcare affordability, directly improve the quality of healthcare delivered, as outlined by the Institute of Medicine.

C S P F
All in the Family: How Genetic Counselors Facilitate Familial Genetic Testing by Amanda Openshaw, MS, LCGC
Number of Credits: 0.5

This lecture provides an introduction to familial genetic testing, meant for non-genetics providers and other healthcare professionals. Standard genetics methodologies are reviewed, and considerations for streamlining test selection and ordering are discussed.

C S P F
Laboratory Ergonomics Programs by Christina K. Kulakowski
Number of Credits: 1.0

Having a strong ergonomics program can help decrease workers compensation claims and improve employee’s performance. This workshop will focus on what ergonomics is and why it is an important element of a comprehensive occupational health and safety program.

We will review proper workstation setup, as well as laboratory ergonomic work practices and principals with a focus on repetitive tasks such as microscope use, pipetting, and miscellaneous hand tool and computer use. Additionally, we will identify what to include in an ergonomics program—from effective training to ergonomic assessments and everything in between.

Additionally, we will discuss specific laboratory case studies and work through problem-solving exercises to identify risk factors in a laboratory setting and how to mitigate the identified risk.

C S P F
Updates in Pancreas by Kajsa Affolter, MD
Number of Credits: 1.0

We will discuss the modifications to the AJCC Cancer Staging Manual 8th edition with regard to both the T and N categories of pancreatic adenocarcinoma, focusing on the reasons for changes and the practical implications. Furthermore, the slight alteration to the classification of neuroendocrine neoplasms in the AJCC Cancer Staging Manual 8th edition will be addressed, with an emphasis on how this impacts the clinical management and prognosis. We will conclude with a brief conversation of various pancreatic cysts and recent suggestions on the best classification system.

C S P F
Understanding Quality Control: A Process Improvement Perspective by Robert Schmidt, MD, PhD, MBA and Lauren N. Pearson, DO, MPH
Number of Credits: CME/SAM: 1.25 PACE: 1.0 Florida: 1.3

This session will provide an understanding of three fundamental concepts of quality control: stability, capability and controllability. The theory of each of these concepts will be described and will be followed with practical advice on how to apply these concepts in the real world. A top level approach to quality improvement will be presented along with practical tools to implement each phase of the quality improvement process. The goal is to provide participants with a practical approach to QC analysis and a roadmap for QC improvement.

C S P F
The End: Challenges in Anal Pathology by Eric A. Swanson, MD
Number of Credits: CME/SAM: 0.75 PACE: 0.5

Discussion of challenges in the diagnosis of anorectal malignancies. Evaluation of the histologic and immunophenotypic findings in various malignant lesions is discussed. The impact of the diagnosis of the various lesions is discussed, with emphasis on the treatment and prognostic implications.

C S P F
Genomic Profiling and New Immunotherapies: An Oncologist’s Perspective by Jonathan Whisenant, MD
Number of Credits: 1.0

The purpose of this lecture is to give pathologists a clinical perspective on how oncologists use molecular testing and biomarkers for therapeutic implications. A review of several trials focuses on tests and therapies that have been FDA approved or appear promising for future approval.

C S P F
Updates in Mastocytosis by Tracy I. George, MD
Number of Credits: CME/SAM: 0.75 PACE: 0.5

In “Updates in Mastocytosis,” Dr. Tracy George discusses the diagnosis, classification, and recent clinical trials work in mast cell disease. This orphan disease has been of intense interest recently with breakthrough therapies based on targeting of the D816V KIT mutation, approved by the FDA and EMA. Dr. George is an international expert in the pathology of mast cell diseases and a founding member of AIM (American Initiatives in Mast Cell Diseases). The inaugural meeting of AIM will occur at Stanford University in May 2019.

C S P F
Tough Love: Managing Your Lab Customers to Improve Relationships and Outcomes by Brian Jackson, MD, MS
Number of Credits: 0.5

How should laboratories treat their clinician customers? On one hand, laboratories want to provide excellent customer service by accommodating their clinical customers’ preferences. On the other hand, laboratories need to enforce standardized processes such as proper specimen submission. This pre-recorded webinar will provide examples from other industries to illustrate how a “tough love” approach can produce high levels of process quality and clinician loyalty at the same time.

C S P F
Genomics Reimagined in a Reference Laboratory Setting by Hunter Best, PhD, FACMG
Number of Credits: 1.0

The field of genomics has evolved at a rapid pace, resulting in many growing pains for clinical laboratories trying to implement massively parallel sequencing-based testing. This presentation will discuss the issues that we have encountered in this area, and how we have modified our processes to address them.

C S P F
Automation and Process Re-Engineering are Required to Achieve Six-Sigma Quality: Our 27-Year History of Continuous Improvement by Charles D. Hawker, PhD, MBA, FACSc, FAACC
Number of Credits: 1.0

This lecture reviews the progress of ARUP Laboratories over a 27 year period to improve the incidence of lost specimens. This effort culminated in reaching Six-Sigma quality, making ARUP the first US clinical lab to achieve this level for any metric, whether analytical or non-analytical. A combination of eight automation stages and 19 process improvement/ engineering control steps enabled this improvement.

C S P F
The Scoop on Biological Testing for Detecting or Confirming Drug-Exposed Newborns - What, When and How? by Gwen McMillin, PhD, DABCC(CC,TC)
Number of Credits: 1.0

Drug use during pregnancy is associated with acute and chronic medical needs for the associated newborn, including management of neonatal abstinence syndrome. This presentation reviews drug use patterns among pregnant women in the United States and options for biological testing to detect drug-exposed newborns. Strengths, challenges, and interpretive tools are discussed with emphasis on meconium and umbilical cord tissue, two newborn specimens that are widely used today.

C S P F
Hepatocellular Carcinoma: Histologic Variants by Sanjay Kakar, MD
Number of Credits: 1.0

Discuss the morphologic features of histologic variants of HCC and combined hepatocellular-cholangiocarcinoma with a focus on advantages and pitfalls of various immunohistochemical markers in recognizing the subtypes. The importance of novel markers including molecular alterations in improving the diagnosis will be discussed.

C S P F
Barrett’s Esophagus in 2018: The Pathologist's Perspective by John Hart, MD
Number of Credits: 1.0

In recent years there has been several changes suggested for the operational diagnosis of Barrett esophagus. In addition, new endoscopic techniques for the detection and management of Barrett esophagus are becoming increasingly utilized in routine clinical practice. These new developments, which have important implications for the practicing surgical pathologist, will be discussed in detail.

C S P F
Deconvoluting the Most Clinically Relevant Region of the Human Genome by Dimitri S. Monos, PhD
Number of Credits: 1.0

The MHC, a segment of 4Mb, is recognized to be the genomic region in the Human Genome associated with the highest number of diseases. Its significance calls for its detailed and thorough characterization. Our recent attempts to characterize the 4Mb of the MHC for heterozygote samples using long sequencing reads (3-10kb) and de novo (not reference-based) assembly is presented. Our eventual objective is the generation of MHC haplotypes, if possible for the whole MHC or any other sizeable sub-segment of interest. Most recently, within the MHC we have identified genomic elements, (like miRNAs) playing important biological role by controlling the expression of many other genes in the cell. Through computational means we have identified a likely large number of miRNAs encoded by the MHC. Could the presence of these elements explain the high density of SNPs, within the MHC, associated with many diseases? Alternative approaches combining NGS/Genetics and Complexity Theory/Physics provide new insights in the relationships of the different genomic sequences (exons/introns/intergenic sequences) and suggest that these sequences encode for elements forming a continuum of information throughout the MHC. We are in the process of identifying both the information and the interactive relationships of the different subsegments of the MHC.

C S P F
Patient Blood Management: At the Forefront of Quality and Value in Healthcare by Ryan A. Metcalf, MD, CQA(ASQ)
Number of Credits: 1.0

Blood transfusion is the most commonly performed procedure in the United States, is often overperformed, and Patient Blood Management (PBM) is now considered standard of care. Per capita health care costs in the United States are double those of many other high-income countries without better outcomes. PBM creates value by simultaneously improving patient outcomes, reducing costs, and improving efficiency. This PBM presentation is in three parts: reducing unnecessary transfusions, comprehensive PBM, and the effective use of data now and in the future.

C S P F
Ethics, Stewardship, and Laboratory Tests with Unproven Clinical Benefit by Brian Jackson, MD, MS
Number of Credits: 1.0

Clinical laboratories often receive orders for tests that are outside the mainstream of clinical testing. Some of these are new/emerging tests for which there simply isn’t a lot of clinical experience. Some are research biomarkers that are primarily of interest to bench scientists. Some are panels or algorithms designed largely in response to marketing considerations. What these all have in common is a lack of clinical evidence demonstrating clinical utility, i.e. therapeutic benefit for patients as a consequence of the tests. How should clinical labs evaluate requests for such tests? Historically many laboratories have approached these requests from a financial and/or logistical perspective, approving the tests as long as they don’t overly burden the local laboratory (and provided that they are performed in a CLIA-licensed setting). This presentation will present an additional framework for consideration, namely bioethics. What is the ethical impact of such testing on the individual patient as well as on society as a whole? And how can potentially useful – but still unproven – laboratory tests be introduced into clinical settings in an ethically consistent manner?

Originally presented on July 10, 2018 as a live Seattle Children's Hospital Webinar Series

C S P F
Clinical Cytogenetic Testing: Applications in Constitutional and Oncology Settings by Erica F. Andersen, PhD, FACMG
Number of Credits: 1.0

Cytogenetic testing is utilized across multiple areas of medicine for the diagnosis of heritable (constitutional) genetic conditions, as well as in cancer, particularly hematologic disease. This presentation will provide an overview on the utility of clinical cytogenetic testing for patients with developmental constitutional disorders, prenatal and perinatal diagnosis, pregnancy loss, and in cancer.

C S P F
Laboratory Stewardship: Taking the First Steps to Downstream Savings by Andrew Fletcher, MD, CPE
Number of Credits: 1.0

This presentation will delve into the concept of lab stewardship and its critical role for the future of laboratory medicine. Dr. Fletcher will also outline several strategies for implementing successful interventions to drive downstream savings in healthcare systems.

C S P F
Introduction to the ABO Blood Group by Justin R. Rhees, MS, MLS(ASCP)CM, SBBCM
Number of Credits: 1.0

The ABO blood group system is the most important in transfusion medicine. This presentation covers basic ABO inheritance, antigen production and expression, and weak subgroups.

C S P F
HIV Update in Laboratory Testing by Patricia R. Slev, PhD
Number of Credits: 1.0

New recommendations for laboratory diagnostic testing for HIV were officially published by the CDC in June 2014. Understanding appropriate test utilization and result interpretation for HIV diagnosis is critical for compliance and patient care. This presentation will address the new algorithm and review the evidence and rationale in support of the new guidelines.

Originally presented on January 30, 2015 and updated on September 6, 2017 in Salt Lake City, Utah

C S P F
Kidney Stones: Diagnosis, Treatment, & Future Prevention by Jessica Corean, MD
Number of Credits: 1.0

Kidney stones are a common medical issue, affecting 1 in 11 people during their lifetime. Stones form when normally soluble material supersaturates in the urine and begins to crystalize. Management is dependent on stone size, but includes hydration, pain medication, and removal of stone. In pediatric patients or repeat stone-forming patients, stone analysis and supersaturation profiles are important for long term management and prevention. There are numerous stone compositions, which can indicate possible underlying pathologies or target therapy. Without appropriate treatment, reoccurring kidney stones can cause permanent renal damage or failure. This presentation provides an overview on kidney stone clinical presentation, laboratory and radiographic findings, composition types, and spontaneous and familial risk factors.

C S P F
Behavior-Based Safety Programs by Christina K. Kulakowski
Number of Credits: 1.0

No short description

C S P F
Autoantibody Testing in the Diagnosis of Autoimmune Neurological Disorders by Lisa K. Peterson, PhD
Number of Credits: 1.0

Autoimmune neurology is a rapidly evolving field, with additional autoantibodies continually being identified. This presentation will focus on the laboratory’s role in diagnosing and managing autoimmune neurologic disorders, including paraneoplastic neurological syndromes (PNS), autoimmune encephalitis, and autoimmune neuromuscular junction disorders. Also discussed will be methods for detecting autoantibodies in serum and CSF, with an emphasis on their strengths and weaknesses, as well as testing strategies for autoimmune neurologic diseases.

C S P F
Employee Mentoring: Fostering a Culture of Contribution by Jo D Fontenot, MS, MT(ASCP)
Number of Credits: 0.5

This lecture will describe the roles of a mentor and protégé. It will evaluate the responsibilities of each member of the partnership to ensure cross functional development within the organizations. It will describe strategies to use when setting up a successful mentoring program.

C S P F
Diagnostic Errors in (Anatomic) Pathology by Michael Cohen, MD
Number of Credits: 1.0

The aim of this presentation is to familiarize listeners with the relatively recently (9/2015) released IOM (Institute of Medicine) report on diagnostic errors and the importance of cognitive errors.

C S P F
Is There a Bully in the Room? by Tiffany A. Bradshaw, MLS(ASCP)CM
Number of Credits: 0.5

This lecture will examine how bullying in the workplace might be defined and specific examples of how these behaviors might be displayed. In addition, methods for addressing and dealing with bullying, as well as current legislative and organizational strategies, will be covered.

C S P F
Elisa Science
Number of Credits: PACE: 1.0 Florida: 1.3

This course describes the Enzyme Linked Immunosorbant Assay (ELISA) testing method used in many analytical tests. Included are descriptions of the testing process and what is being tested. Animations are used to help illustrate what is happening at the molecular level.

C S P F
Introduction to Antibody Identification by Justin R. Rhees, MS, MLS(ASCP)CM, SBBCM
Number of Credits: 1.0

Several effective approaches to antibody identification in the routine blood bank exist. This presentation explains a conservative approach to antibody identification and several demonstrations of ruling out, choosing appropriate selected cells, and completing antibody workups are given.

C S P F
Cost-Effectiveness Analysis of Laboratory Tests by Robert Schmidt, MD, PhD, MBA
Number of Credits: 1.0

Laboratories are under intense pressure to increase value. Cost-effectiveness analysis (CEA) can help labs increase value by identifying optimum testing scenarios. This webinar explains important concepts such as cost-perspectives, methods for estimating costs, estimating outcomes, evaluating outcomes, and evaluating uncertainty in model outputs. At the end of this lecture, viewers will understand the different types of frameworks and analyses that are used in cost-effectiveness analysis.

C S P F
The Lewis System by Justin R. Rhees, MS, MLS(ASCP)CM, SBBCM
Number of Credits: 0.5

The Lewis system is unique among blood group systems in that the antigens are not manufactured within the erythrocyte, nor do they form an integral part of the cytoskeletal membrane. Rather, they are synthesized by tissues, secreted into blood and body fluids, and adsorb onto the red blood cell. While antibodies against antigens in this system are fairly commonly encountered, they are generally not considered to be clinically significant in transfusion. In vitro and in vivo hemolysis are rare but have been reported. Because Lewis phenotype expression is based upon the interaction of several genes, and because the phenotype expression can be transient, the Lewis system is a fascinating system to learn about.

C S P F
Diagnostic Approach to Anemia by Archana Mishra Agarwal, MD
Number of Credits: PACE: 1.0 Florida: 1.3

The understanding of anemias is very important as clinicians attempt to provide high quality medical care to their patients. The medical laboratory scientist must also understand anemias to provide the needed information to physicians. This lecture will address the basics of the classification of anemias and tools used in the medical laboratory to assess a patient’s blood health or presence of anemia.

C S P F
Hematology M+Ms: Morphology and Mystery (Case Studies) by Karen A. Brown, MS, MLS(ASCP)CM
Number of Credits: 1.0

Hematology instrumentation has advanced to now routinely include at least a five-part differential and, in some laboratories, automated cell image analysis. Yet, a manual examination of the blood smear is still an essential procedure that provides valuable diagnostic information. This session will use case studies to define important morphologic variations and physiologic processes in selected disease conditions.

C S P F
The Illusion of Quality: A Discussion of Roadblocks to Laboratory Quality and Case Studies of How to Make Things Better by Frederick G. Strathmann, PhD, DABCC (CC, TC)
Number of Credits: 1.0

The purpose of this presentation is to emphasize the need for every laboratory to continuously review its quality processes. The recent changes surrounding Equivocal QC practices provide an opportunity for laboratories to ensure minimum requirements are met and a chance to move towards raising the bar internally for quality requirements. Practical and real-world examples of how to prepare, implement, and measure the impact of changing quality will be presented and discussed.

C S P F
Laboratory Formularies: Improving Care, Reducing Costs by Brian R. Jackson, MD, MS
Number of Credits: 0.5

Laboratory formularies are an emerging tool for promoting effective use of the clinical laboratory. This presentation covers the key considerations for developing, applying, and managing a lab formulary: governance, process, evidence base, and analytics. In the end, a formulary is not so much a product as it is an interconnected system for managing and influencing diagnostic practices.

C S P F
The Value of the Laboratory: Invest or Outsource? by Suzanne Carasso, MBA, MT (ASCP)
Number of Credits: 1.0

The impact of national healthcare reform, is putting pressure on the healthcare industry to navigate reductions in reimbursement, implement cost-cutting initiatives and improve patient outcomes and quality of life. Changing the way healthcare is delivered and paid for is the new imperative.

Laboratories, now more than ever before, have a unique opportunity to substantially impact both short and long term sustainability of healthcare organizations. However, labs that continue to just produce lab test results will be viewed as a commodity and will likely be outsourced or sold. Some organizations are selling laboratory and outreach operations to private equity firms, joint venture capitalists or national laboratories in exchange for an immediate and significant infusion of cash. It follows that laboratories failing to demonstrate value to the organization face an uncertain future.

This presentation will inform attendees of the industry trends that are influencing these decisions, the risks laboratories face and what labs can do to demonstrate value in tangible ways.

C S P F
Testing a Test: Beyond Sensitivity and Specificity by Robert Schmidt, MD, PhD, MBA
Number of Credits: 1.0

In this lecture, Dr. Schmidt covers performance evaluation of diagnostic tests. Traditional performance measures such as sensitivity, specificity and ROC curves are reviewed. Reasons for differences in diagnostic studies are examined including real differences, threshold effects, sources of bias, and random variation. Shortcomings of the traditional approaches to test evaluation are also discussed and alternative approaches such as diagnostic research (vs test research), clinical trial evaluation, and cost-effectiveness evaluation are presented.

C S P F
Diagnostic Error & Laboratory Testing by Mark L. Graber, MD, FACP
Number of Credits: 1.0

Diagnostic error is a major patient safety concern, causing substantial harm and unnecessary medial costs. In every large organization, cases related to diagnostic error make up the largest fraction of filed claims and suits. Although the error rate is not being measured in any setting, it is estimated that 1 in 10 diagnoses is wrong, significantly delayed, or missed altogether. The root causes of diagnostic error include many system-based factors (eg breakdowns in communication, coordinating care, having expertise available when needed, supervision of trainees, etc) as well as cognitive shortcomings. The cognitive errors mostly derive from failures to synthesize the available evidence and inappropriate trust of intuition. Errors related to diagnostic testing are common, and include mistakes by the patient’s doctor (not knowing the best test to order or how to interpret it) as well as problems performing and interpreting the test results by the clinical lab or the Radiology department staff. Many interventions to reduce diagnostic error have been proposed, although few have been rigorously evaluated in clinical practice.

C S P F
The Delta Check in Action: Causes and Consequences of Discrepant Laboratory Results by Joely A. Straseski, PhD, MS, MT(ASCP), DABCC
Number of Credits: 1.0

Discrepant results are often identified by delta check alerts. Delta checks compare current laboratory results to previous results; if the difference between the two values exceeds predetermined biological limits (within a predetermined length of time), a technologist is alerted and the discrepancy can be investigated further. Causes of discrepant laboratory results include both preanalytical and analytical issues, as well as true biological changes occurring within the patient.

Many preanalytical issues cannot be detected by traditional QC methods, leading to the possible reporting of erroneous laboratory results. The wrong result compromises patient care by leading to inappropriate diagnoses or treatment. Delta check alerts provide an additional means to identify these types of problems, in addition to alerting health care providers to true changes in their patient’s condition.

C S P F
Laboratory Results - Beyond Patient Testing by Cheryl Vincent, MBA
Number of Credits: 1.0

Clinical Laboratory Scientists are trained to perform laboratory tests and to troubleshoot and validate the results of those tests which contribute to a patient’s medical diagnosis. During this presentation, we will compare the steps involved in pre-analytical, analytical, and post-analytical laboratory testing to the steps involved in pre-analytical, analytical, and post-analytical phases of developing leaders in the clinical laboratory.

C S P F
Blood Bank vs Piggy Bank: Keys to Harmonizing Margin and Mission by Kent Gordon, CPA, MAcc
Number of Credits: 1.0

Tired of fighting with the finance department to get the resources you need to carry out your mission? Ever feel that your CFO is from a different planet and that you just can’t communicate? Do financial concerns kill creativity and stifle progress in your organization? Where is the peace? Where is the love?

This lecture will give you practical tips and tools to help your organization balance operational and financial considerations. First, this course unlocks the mysterious world of accounting . . . revealing the core principles, objectives, and concepts of this centuries-old art. Next, we tackle the sometimes thorny subject of “Margin” verses “Mission” providing some useful prospective on this important topic. Next, we shatter the language barrier, giving you simple terms and lingo to facilitate financial communications. Soon you’ll be fluent in the latest accounting jargon. Finally, we conclude with some take-home financial analysis tools that will have your finance people saying: “Wow! – How’d you get so darn smart?!!!”

C S P F
Are You a Customer Service “Have” or “Have Not”? by Cherie V. Petersen, BA
Number of Credits: 1.0

This shouldn’t be shocking news to most healthcare professionals, but customer service IS a critical function of quality patient care. However, when we as laboratorians think about customer service activities and how that translates into patient care, we tend to think it’s just about what occurs in the literal presence of patients. So, here’s what may be news to some, the patient experience isn’t just about what we do when we’re in their physical presence, but also what we do as we interact with everyone who is in any way associated with their care. Therefore, we must make every effort to be engaged in skilled customer service activities with everyone, at all times. Now, the question may arise, what ARE the necessary skills and activities for providing great customer service (i.e., quality patient care) and how well do YOU execute them? This session will provide an opportunity for self-assessment utilizing a customer service skills preferred profile and an interactive discussion regarding the do’s and don’ts for outstanding customer service.

C S P F
Designing for Improvement by Bonnie Messinger, CPHQ, CMQ/OE (ASQ), Six Sigma Black Belt
Number of Credits: 0.5

Our traditional response to complex problems is to find and eliminate the human behaviors that we think are responsible for errors, and are perplexed when the error we thought we eradicated occurs again and again. We ignore the fact that 95% of process performance is attributable to the design of the work and the system in which the work resides and only 5% to the human component. The importance of creative design in the laboratory is often overlooked and its potential is underutilized. In this session we will discover how to design a work environment where error is, if not impossible, at least very difficult. Using innovative problem solving principles and techniques, we will open the door to organizational excellence by design.

C S P F
Review of Malaria and Plasmodium Species by DeVon C. Hale, MD
Number of Credits: 1.0

This is a basic overview of the disease malaria and the causative agents, Plasmodium species. The life cycles of the parasites and their differentiating characteristics in the human host are discussed, for Plasmodium falciparum. P. ovale, P. vivax, P. malariae. Case studies demonstrate the disease states caused by each species.

C S P F
Phlebotomy Ps and Qs: Problems and Quandaries in Specimen Collection by Karen A. Brown, MS, MLS(ASCP)CM
Number of Credits: 1.0

Phlebotomists routinely encounter dangerous conditions, problem patients, and other issues during blood collection. This session will suggest techniques that can help you avoid or safely manage these difficulties. Areas to be discussed include:

  • risks associated with venous blood collection, such as improper vein selection and needlestick exposure
  • unusual patient situations that impact phlebotomy practice, including the cancer and bariatric patient
  • communication barriers and methods to improve patient interactions, like developing good listening skills and effective communication approaches with the elderly

Designed for phlebotomists and phlebotomy students who have comprehension of the basics of the venipuncture technique, this session will enhance your skills, build your knowledge base, and help you deliver the highest quality in patient care.

C S P F
Reporting Laboratory Errors Without Fear by Lucinda Manning, BA, MT(ASCP), RN
Number of Credits: 1.0

Employees being able to report laboratory errors without fear is a key component of an effective error management system. This presentation will focus on the necessity for making the system useful and easy to use. Case studies are used to discuss a variety of errors and to illustrate how identification of errors can lead to practical solutions in error prevention. A just culture vs. punitive culture will be addressed along with ideas for getting employee “buy-in”. Additionally, strategies for mentoring and coaching employees with high error rates will be provided.

C S P F
Diagnosing Specimen Collection Issues by Ken Curtis, BS PBT(ASCP)
Number of Credits: 1.0

Errors in specimen collection result in inaccurate results. This presentation focuses on identifying specimen collection issues and strategies for preventing them. We will discuss common errors in patient identification, phlebotomy techniques, and specimen labeling. We will also discuss identifying collection issues via pre-analytical processes, training for accuracy in collection, and monitoring improvement.

C S P F
The Human Side of Change Management by Cheryl Vincent, MBA
Number of Credits: 1.0

When we bring up the topic of change, we often think of it as a negative. But why? We’re not opposed to changing a hairstyle, the color of our hair, changing cars, or even changing jobs. Now cell phone contracts are starting to lighten up so we can have a new cell phone almost every six months. There has been a lot of information written about the logical steps to change, but what about the human side of change? Cheryl Vincent will discuss the steps to change but also add a human dimension to the concept of Change Management.

C S P F
When Professionals Meet: Bridging the Gap Between the Laboratory and Nursing by Lucinda Manning, BA, MT(ASCP), RN
Number of Credits: 1.0

Ms. Manning will give a comparison of the differences in learning in the laboratory and nursing professions. She will share personal examples of the struggles each profession has in understanding each other. She will also discuss practical ways to bridge the gaps in understanding between the two professions. Ms. Manning encourages the audience to be interactive and to share problems as well as best practices and successes in bridging the gap between these two professions.

C S P F
Error Proofing the Laboratory by Bonnie Messinger, CPHQ, CMQ/OE (ASQ), Six Sigma Black Belt
Number of Credits: 1.0

Eradicating error in healthcare may seem like a Sisyphean task, yet legislators, regulators and the public in general expect error-free work from medical professionals. How to work without error is the subject of countless lectures, papers and studies, encompassing every discipline from manufacturing to service. The Toyota Production System of quality manufacturing uses the term "poke-yoke" (mistake-proofing) to describe the process of eliminating production defects. "Error-Proofing in Healthcare" will distill and discuss the essential elements of "poke-yoke", starting with defining and exploring the types of error most often encountered in the provision of medical care. Proven improvement tools and techniques for ensuring quality outputs will be presented with practical applications to place the error-proofing strategy in the context of the laboratory.

C S P F

***The archived video lectures listed below no longer provide
continuing education credit
since their CE certification has expired.***